Park Avenue Securities LLC Buys Shares of 2,176 BioNTech SE (NASDAQ:BNTX)

Park Avenue Securities LLC bought a new stake in BioNTech SE (NASDAQ:BNTX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,176 shares of the company’s stock, valued at approximately $201,000.

Several other large investors also recently bought and sold shares of the company. Baillie Gifford & Co. grew its holdings in BioNTech by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after purchasing an additional 86,343 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after acquiring an additional 131,490 shares in the last quarter. Harding Loevner LP purchased a new stake in shares of BioNTech in the fourth quarter valued at $410,984,000. Flossbach Von Storch AG lifted its position in shares of BioNTech by 1.0% in the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock valued at $374,526,000 after acquiring an additional 35,445 shares in the last quarter. Finally, Capital World Investors lifted its position in shares of BioNTech by 1.5% in the fourth quarter. Capital World Investors now owns 938,747 shares of the company’s stock valued at $99,075,000 after acquiring an additional 14,027 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

BioNTech stock opened at $78.76 on Wednesday. The stock’s 50-day moving average is $91.84 and its 200-day moving average is $94.31. The company has a market cap of $18.72 billion, a price-to-earnings ratio of 157.52 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. BioNTech SE has a 12 month low of $78.02 and a 12 month high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The firm had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Equities analysts anticipate that BioNTech SE will post -2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BNTX. BMO Capital Markets reduced their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. JPMorgan Chase & Co. reduced their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. Evercore ISI assumed coverage on BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. UBS Group reduced their target price on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $111.70.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.